ABSTRACT

Introduction

Tecovirimat (TPOXX®; ST-246) was approved for the treatment of symptomatic smallpox by the USFDA in July of 2018 and has been stockpiled by the US government for use in a smallpox outbreak. While there has not been a reported case of smallpox since 1978 it is still considered a serious bioterrorism threat.

Areas covered

A brief history of smallpox from its proposed origins as a human disease through its eradication in the late 20th century is presented. The current smallpox threat and the current public health response plans are described. The discovery, and development of tecovirimat through NDA submission and subsequent approval for treatment of smallpox are discussed. Google Scholar and PubMed were searched over all available dates for relevant publications.

Expert opinion

Approval of tecovirimat to treat smallpox represents an important milestone in biosecurity preparedness. Incorporating tecovirimat into the CDC smallpox response plan, development of pediatric liquid and intravenous formulations, and approval for post-exposure prophylaxis would provide additional health security benefit.

Tecovirimat shows broad efficacy against orthopoxviruses in vitro and in vivo and could be developed for use against emerging orthopoxvirus diseases such as monkeypox, vaccination-associated adverse events, and side effects of vaccinia oncolytic virus therapy.

中文翻译：

---

用于天花治疗和扩展抗正痘病毒应用的 tecovirimat 概述

摘要

介绍

Tecovirimat (TPOXX®; ST-246) 于 2018 年 7 月被美国食品药品监督管理局批准用于治疗症状性天花，并已被美国政府储备用于天花爆发。虽然自 1978 年以来没有报告过天花病例，但它仍然被认为是一种严重的生物恐怖主义威胁。

涵盖的领域

介绍了天花从被认为是一种人类疾病的起源到 20 世纪后期被根除的简史。描述了当前的天花威胁和当前的公共卫生应对计划。讨论了通过提交 NDA 和随后批准用于治疗天花的 tecovirimat 的发现和开发。谷歌学术和 PubMed 搜索了所有可用日期的相关出版物。

专家意见

批准 tecovirimat 治疗天花代表了生物安全防范的一个重要里程碑。将 tecovirimat 纳入 CDC 天花应对计划、开发儿科液体和静脉注射制剂以及批准暴露后预防将提供额外的健康安全益处。

Tecovirimat 在体外和体内显示出对正痘病毒的广泛功效，可用于治疗新出现的正痘病毒疾病，如猴痘、疫苗相关的不良事件和牛痘溶瘤病毒治疗的副作用。